

Follow these 3 steps to enroll and participate in the ESA* APPRISE Oncology Program:


Failure to comply with the ESA APPRISE Oncology Program requirements will result in suspension of your access to ESAs (Aranesp® and Epogen®/Procrit®).



1

Train

Complete the ESA APPRISE Oncology Program training, which includes a review of the risks of ESA therapy and appropriate use of ESAs for patients with cancer.



2

Enroll

Enroll in the ESA APPRISE Oncology Program by completing the ESA APPRISE Oncology Program Enrollment Form for Healthcare Providers.



3

Counsel and Document

Prior to each new course of ESA therapy:

- Counsel each patient on the risks of ESAs using the ESA APPRISE Oncology Program Patient and Healthcare Provider Acknowledgment Form (Acknowledgment Form)†. Review ESA risk:benefit information with each patient and answer any questions they may have.
- Document that the ESA risk:benefit discussion occurred using the Acknowledgment Form. Complete each section of the Acknowledgment Form with each patient and provide each patient a copy of the signed form.
- Make completed Acknowledgment Forms available to the ESA APPRISE Oncology Program for auditing purposes in a manner that does not disclose patients' medical records.
- In a private practice-based clinic, store and archive the forms so that they are retrievable, whether physically on-site or electronically.
- In a hospital, provide the completed form to the Hospital Designee responsible for maintaining and storing the forms.

To train and enroll, contact your local Amgen or Janssen Products, LP Field Representative or access the ESA APPRISE Oncology Program website at www.esa-apprise.com. If you are unable to enroll via a Field Representative or online, please call the ESA APPRISE Oncology Program Call Center at 1-866-284-8089 for further assistance.

Please see the Aranesp®, Epogen® and Procrit® prescribing information, including **Boxed WARNINGS** and Medication Guides available at www.esa-apprise.com.

*ESA = erythropoiesis stimulating agent [Aranesp® (darbepoetin alfa)/Epogen® (epoetin alfa)/Procrit® (epoetin alfa)].

†Or modified version consistent with allowable changes.

Aranesp® and Epogen®/Procrit® are different drugs with distinct dosing schedules.

Aranesp® and Epogen® are registered trademarks of Amgen Inc. Procrit® is a registered trademark of Janssen Products, LP.

This document has been required by the US Food and Drug Administration as part of a Risk Evaluation and Mitigation Strategy (REMS)

Reference ID: 3429792 and Procrit®.

ESA APPRISE
ONCOLOGY PROGRAM

Assisting Providers and cancer Patients with
Risk Information for the Safe use of ESAs